$32.950
-0.646 (-1.96%)收盘时
AZTA 资讯
AZTA 事件
Company Reaffirms Q4 Total Revenue Guidance
The Company is reaffirming its Q4 total revenue guidance previously issued on August 4: total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to last year. The Company now expects Q4 adjusted EBITDA to be impacted by a one-time approximately $3M consulting expense that will be recorded in the Q4. Excluding this one-time charge, the Company would be reaffirming adjusted EBITDA as well.
Azenta Appoints Martin Madaus as Interim CEO
Azenta (AZTA) announced that current member of the Board of Directors Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company. Madaus has served in multiple CEO roles in the diagnostics and life science tools industry and joined the Azenta Board in 2024 - making him the ideal individual to lead the Company during this transition. He is a Senior Operating Executive at the Carlyle Group (CG) and has a proven track record of creating shareholder value in both public and private life science companies. Notably, he has served as Chairman, President and CEO of Millipore Corporation, Chairman and CEO of Ortho-Clinical Diagnostics, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG. The Board has retained search firm Heidrick & Struggles, and a search process for a permanent CEO is underway.
Company Q3 Revenue Exceeds Expectations at $161M
Reports Q3 revenue $161M, consensus $149.23M. "Despite an uneven and challenging market backdrop, our third quarter results exceeded our expectations, with continued strength in our recurring revenue businesses, and a modest improvement in Multiomics in North America," said John Marotta, President and Chief Executive Officer. "While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."
Company Expects Organic Revenue Flat to Up 1% for FY2025
Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range approximately between flat to up 1%, compared to prior guidance of down 2% to up 1% relative to fiscal 2025. Organic revenue for Sample Management Solutions is expected to grow low-single-digits, consistent with prior guidance. Organic revenue for Multiomics is now expected to range approximately between down 1% to flat, compared to prior guidance of down mid-single-digits.
Total Organic Revenue Expected to Decline in Q4 FY2025
Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to the fourth quarter of fiscal 2025.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。